Literature DB >> 18521298

Confirmed angiosarcoma: prognostic factors and outcome in 50 prospectively followed patients.

N J Espat1, J J Lewis, J M Woodruff, C Antonescu, J Xia, D Leung, M F Brennan.   

Abstract

Purpose. Angiosarcoma is a rare tumor with endothelial cell differentiation that may arise in any anatomic location.The purpose of this report was to identify prognostic factors on outcome in a group of prospectively followed patients with confirmed angiosarcoma.Subjects. Adult patients (>16 years old) with angiosarcoma treated between July 1982 and February 1998 were identified from a prospective database.Methods. Pathologic confirmation of all cases was performed prior to inclusion in this analysis. Various prognostic factors were evaluated for disease-specific survival. Survival was determined by the Kaplan- Meier method. Statistical significance was evaluated by log-rank test for univariate analysis and Cox stepwise regression for multivariate analysis (p<0.05).Results. Fifty patients were identified; at the initial evaluation, this group included 32 patients with a primary tumor, three with local recurrence and 15 with metastatic disease. Tumor sites included 16 head and neck and skin of head, eight extremity, seven trunk, six breast, five pelvis, four viscera and four thoracic. Median follow-up among survivors was 71 months (range, 38-191 months).Two- and 5-year disease-specific survival was 50 and 30%, respectively, with a median of 24 months. The factor predictive of tumor-related mortality was presentation status (p=0.001; relative risk, 5). Two-year disease-specific survival for patients presenting with recurrent or metastatic disease was 13%, compared with 70% for those with primary disease.

Entities:  

Year:  2000        PMID: 18521298      PMCID: PMC2395443          DOI: 10.1080/13577140020025896

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  12 in total

1.  Long-term risk of sarcoma following radiation treatment for breast cancer.

Authors:  A Taghian; F de Vathaire; P Terrier; M Le; A Auquier; H Mouriesse; E Grimaud; D Sarrazin; M Tubiana
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-07       Impact factor: 7.038

Review 2.  Soft tissue sarcomas.

Authors:  J J Lewis; M F Brennan
Journal:  Curr Probl Surg       Date:  1996-10       Impact factor: 1.909

3.  Association of local recurrence with subsequent survival in extremity soft tissue sarcoma.

Authors:  J J Lewis; D Leung; M Heslin; J M Woodruff; M F Brennan
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  The rationale for planned reoperation after unplanned total excision of soft-tissue sarcomas.

Authors:  A E Giuliano; F R Eilber
Journal:  J Clin Oncol       Date:  1985-10       Impact factor: 44.544

5.  Vascular soft-tissue sarcomas. An analysis of tumor-related mortality.

Authors:  M S Karpeh; C Caldwell; J J Gaynor; S I Hajdu; M F Brennan
Journal:  Arch Surg       Date:  1991-12

6.  Angiosarcoma of skin and soft tissue: a study of forty-four cases.

Authors:  J C Maddox; H L Evans
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

7.  Angiosarcoma of the head and neck.

Authors:  W M Lydiatt; A R Shaha; J P Shah
Journal:  Am J Surg       Date:  1994-11       Impact factor: 2.565

8.  Angiosarcoma in Japan. A review of 99 cases.

Authors:  N Naka; M Ohsawa; Y Tomita; H Kanno; A Uchida; K Aozasa
Journal:  Cancer       Date:  1995-02-15       Impact factor: 6.860

9.  The role of multimodality therapy in soft-tissue sarcoma.

Authors:  M F Brennan; E S Casper; L B Harrison; M H Shiu; J Gaynor; S I Hajdu
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

10.  Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases.

Authors:  N Naka; M Ohsawa; Y Tomita; H Kanno; A Uchida; A Myoui; K Aozasa
Journal:  J Surg Oncol       Date:  1996-03       Impact factor: 3.454

View more
  17 in total

1.  Orthopaedic case of the month: A 30-year-old woman with a painful forearm mass.

Authors:  J Hochfelder; L D Rybak; R Garcia; J C Wittig
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

2.  Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma.

Authors:  Sandra P D'Angelo; Rodrigo R Munhoz; Deborah Kuk; Johnathan Landa; Eliza W Hartley; Michael Bonafede; Mark A Dickson; Mrinal Gounder; Mary L Keohan; Aimee M Crago; Cristina R Antonescu; William D Tap
Journal:  Oncology       Date:  2015-06-03       Impact factor: 2.935

3.  Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan.

Authors:  Takamichi Ito; Hiroshi Uchi; Takeshi Nakahara; Gaku Tsuji; Yoshinao Oda; Akihito Hagihara; Masutaka Furue
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-25       Impact factor: 4.553

4.  Cutaneous angiosarcoma: a single-institution experience.

Authors:  Matthew C Perez; Tapan A Padhya; Jane L Messina; Ryan S Jackson; Ricardo J Gonzalez; Marilyn M Bui; G Douglas Letson; C W Cruse; Robert S Lavey; David Cheong; Meghan R Forster; William J Fulp; Vernon K Sondak; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2013-07-09       Impact factor: 5.344

5.  Angiosarcoma of the seminal vesicle: a case report of long-term survival following multimodality therapy.

Authors:  Kenneth Chang; Terence T Sio; Vishal S Chandan; Matthew J Iott; Christopher L Hallemeier
Journal:  Rare Tumors       Date:  2014-01-29

6.  Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature.

Authors:  Ping Yang; Qi Zhu; Fuqiang Jiang
Journal:  Chin J Cancer Res       Date:  2013-06       Impact factor: 5.087

7.  Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp.

Authors:  B Ashleigh Guadagnolo; Gunar K Zagars; Dejka Araujo; Vinod Ravi; Thomas D Shellenberger; Erich M Sturgis
Journal:  Head Neck       Date:  2010-10-19       Impact factor: 3.147

8.  CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 cases.

Authors:  Meghna Alimchandani; Zeng-Feng Wang; Markku Miettinen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014 May-Jun

9.  Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway.

Authors:  Andrew Courtwright; Sharareh Siamakpour-Reihani; Jack L Arbiser; Natalie Banet; Eleanor Hilliard; Levi Fried; Chad Livasy; David Ketelsen; Desh Bandhu Nepal; Charles M Perou; Cam Patterson; Nancy Klauber-Demore
Journal:  Cancer Res       Date:  2009-05-19       Impact factor: 12.701

10.  A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth.

Authors:  Emily Fontenot; Emma Rossi; Russell Mumper; Stephanie Snyder; Sharareh Siamakpour-Reihani; Ping Ma; Eleanor Hilliard; Bradley Bone; David Ketelsen; Charlene Santos; Cam Patterson; Nancy Klauber-DeMore
Journal:  Mol Cancer Ther       Date:  2013-04-19       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.